Seems the Avandia ship is not going to right itself. More bad news today, and sales of the formerly popular diabetes drug have taken a nose dive. Commentators have already taken to using the Avandia headlines as an excuse to talk FDA reform. Will we see movement this time?
Have you registered with us yet?
Register now to enjoy more articles and free email bulletins